Compare Ascendis Pharma A/S (ASND) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Ralph Lauren Corp — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Ralph Lauren Corp trades at $389.93 (market cap $23.50B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.95% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RL | |
|---|---|---|
Market Cap | $17.74B | $23.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $414.25 |
52-Week Low | $163.32 | $283.34 |
Enterprise Value | $18.11B | $24.45B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Ralph Lauren (RL) trades at $394.9, up 1.89% today, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows strong fundamentals with a 10.49% net income margin and 34.66% ROE, though technical indicators signal near-term bearish pressure. Recent news highlights brand momentum in Asia and digital expansion under its Next Great Chapter plan, supporting growth prospects.
The outlook is positive given consistent earnings beats and analyst consensus favoring a buy rating with a $446.25 price target, implying 13% upside. Key risks include premium valuation multiples and macroeconomic headwinds affecting consumer discretionary spending, but strong cash flow and margin expansion provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
